RXRXHealthcareSmall-Cap
RECURSION PHARMACEUTICALS, INC. Insider Trading Activity
Every SEC Form 4 insider transaction reported for RECURSION PHARMACEUTICALS, INC. (RXRX), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are RXRX insiders buying or selling?
RECURSION PHARMACEUTICALS, INC. insiders reported 19 open-market buys ($64.7M) and 213 sells ($65.6M) across 232 Form 4 filings — a net selling position of $864.6K.
Source: SEC EDGAR Form 4
Key Statistics (as of Jul 9, 2026)
Total Form 4 filings
232
SEC EDGAR
Insider filers
13
Insider buys (19)
$64.7M
Insider sells (213)
$65.6M
Insider sentiment
Net sellingNet insider flow of $864.6K in net selling.
Recent RXRX insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 9, 2026 | Blake Borgeson | Director | Sale | 40.0K | $3.96 | $158.5K |
| Jun 22, 2026 | Namandje Bumpus | Director | Sale | 4.0K | $3.18 | $12.6K |
| Jun 5, 2026 | Christopher Gibson | Director | Sale | 40.0K | $3.62 | $144.8K |
| Jun 5, 2026 | Najat Khan | CEO and President | Sale | 23.6K | $3.58 | $84.5K |
| Jun 4, 2026 | Namandje Bumpus | Director | Sale | 4.4K | $3.54 | $15.5K |
| Jun 4, 2026 | Blake Borgeson | Director | Sale | 30.0K | $3.68 | $110.4K |
| May 27, 2026 | Christopher Gibson | Director | Sale | 40.0K | $3.08 | $123.2K |
| May 8, 2026 | Christopher Gibson | Director | Sale | 40.0K | $3.37 | $134.8K |
| May 7, 2026 | Blake Borgeson | Director | Sale | 30.0K | $3.52 | $105.6K |
| Apr 24, 2026 | Christopher Gibson | Director | Sale | 40.0K | $3.61 | $144.4K |
| Apr 8, 2026 | Christopher Gibson | Director | Sale | 40.0K | $3.10 | $124.0K |
| Apr 8, 2026 | Blake Borgeson | Director | Sale | 30.0K | $3.10 | $93.0K |
| Mar 25, 2026 | Christopher Gibson | Director | Sale | 40.0K | $3.25 | $130.0K |
| Mar 18, 2026 | Ben R Taylor | Chief Financial Officer | Sale | 8.0K | $3.39 | $27.0K |
| Mar 11, 2026 | Najat Khan | CEO and President | Sale | 28.3K | $3.35 | $94.7K |
| Mar 4, 2026 | Blake Borgeson | Director | Sale | 170.0K | $3.46 | $588.2K |
| Feb 20, 2026 | Christopher Gibson | Director | Sale | 40.0K | $3.46 | $138.4K |
| Feb 20, 2026 | Ben R Taylor | Chief Financial Officer | Sale | 13.4K | $3.08 | $41.4K |
| Feb 6, 2026 | Christopher Gibson | Director | Sale | 40.0K | $4.12 | $164.8K |
| Feb 6, 2026 | Blake Borgeson | Director | Sale | 220.0K | $4.20 | $924.0K |
| Jan 23, 2026 | Christopher Gibson | Director | Sale | 40.0K | $4.47 | $178.8K |
| Jan 8, 2026 | Blake Borgeson | Director | Sale | 220.0K | $4.36 | $959.2K |
| Jan 7, 2026 | Christopher Gibson | Director | Sale | 40.0K | $4.25 | $170.0K |
| Dec 31, 2025 | Ben R Taylor | Chief Financial Officer | Sale | 21.4K | $4.18 | $89.4K |
| Dec 29, 2025 | Najat Khan | Chief R&D Commercial Officer | Sale | 124.4K | $4.41 | $548.6K |
Showing the 25 most recent of 232 Form 4 filings for RECURSION PHARMACEUTICALS, INC..
Most active RXRX insiders
- Christopher Gibson76 filings
- Blake Borgeson62 filings
- Tina Marriott27 filings
- Mubadala Investment Co PJSC18 filings
- Michael Secora17 filings
Ask anything about RXRX insider activity
Use Trabud's AI agent to query RECURSION PHARMACEUTICALS, INC.'s Form 4 history in plain English — "Show me RXRX CEO purchases this year" or compare it against any other ticker.
Open the AI agentRXRX insider trading FAQ
Are RECURSION PHARMACEUTICALS, INC. insiders buying or selling?
Across 232 SEC Form 4 filings, RECURSION PHARMACEUTICALS, INC. (RXRX) insiders reported 19 open-market purchases totaling $64.7M and 213 sales totaling $65.6M. That is a net selling position of $864.6K.
How many insiders trade RXRX stock?
13 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for RECURSION PHARMACEUTICALS, INC.. The most recent filing was accepted on Jul 9, 2026.
Where does Trabud get RXRX insider trading data?
All RXRX insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.